English
Nederlands
Français
Deutsch
Italiano
Русский
Español
简体中文
हिन्दी
日本語
Pfizer
shares were falling early Wednesday after the pharmaceutical company revised its guidance for 2024. Its new earnings and revenue projections were below expectations, although it raised its cost-saving targets.
Pfizer
said it expects adjusted earnings per share in the range of $2.05 to $2.25 for 2024. The consensus was for adjusted earnings of $3.16 a share, according to a FactSet poll of analysts’ estimates.
Pfizer said it expects revenue in the range of $58.5 billion to $61.5 billion in 2024 including the expected contribution from cancer-focused
Seagen,
which it agreed to acquire for $43 billion earlier this year. Analysts had forecast 2024 revenue of $62.66 billion.
Pfizer shares were down 6.8% at $26.63 in premarket trading.
Pfizer CEO Albert Bourla said in a statement that the company’s product portfolio remains strong.
“We expect our cost realignment program to deliver savings of at least $4 billion by the end of 2024, which puts us on a path to potentially regain our prepandemic operating margins,” Bourla said.
The new cost-savings target was increased by $500 million from Pfizer’s guidance provided in August.
Pfizer projected revenue of $8 billion for its Comirnaty and Paxlovid treatments for Covid in 2024 and growth of between 8% to 10% in operating revenue for its combined Seagen and Pfizer portfolio of other products.
Excluding revenue from Comirnaty and Paxlovid and the expected contribution from Seagen, Pfizer expects to achieve full-year 2024 operating revenue growth of 3% to 5%
Write to Adam Clark at adam.clark@barrons.com
Read the full article here
